Harvard Bioscience, Inc.
HBIO
$0.489
$0.01292.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -437.61% | -564.88% | -263.25% | -336.44% | -96.68% |
| Total Depreciation and Amortization | -4.09% | -0.38% | 2.27% | -0.11% | -2.74% |
| Total Amortization of Deferred Charges | 88.57% | 38.57% | 16.79% | 6.79% | 0.00% |
| Total Other Non-Cash Items | 691.27% | 599.06% | 13.14% | 74.46% | 51.21% |
| Change in Net Operating Assets | 2.08% | -75.42% | -98.59% | -19.16% | 167.00% |
| Cash from Operations | -28.16% | -77.80% | -89.73% | -67.61% | 6.09% |
| Capital Expenditure | 28.96% | -13.72% | -47.87% | -165.97% | -77.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | -100.00% |
| Other Investing Activities | -155.43% | 789.32% | 348.57% | 522.60% | 1,286.11% |
| Cash from Investing | -102.85% | 22.06% | 25.29% | -99.28% | -21.20% |
| Total Debt Issued | -56.95% | 14.55% | 95.56% | 180.00% | 51.00% |
| Total Debt Repaid | 70.53% | 57.46% | 43.00% | 24.27% | -9.98% |
| Issuance of Common Stock | -45.85% | -56.60% | -59.14% | -55.50% | -59.76% |
| Repurchase of Common Stock | 72.17% | 74.94% | 77.13% | -133.66% | -64.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 77.85% | 97.28% | 98.92% | 73.11% | -1.61% |
| Foreign Exchange rate Adjustments | 286.64% | 164.22% | 56.25% | 108.21% | -6,650.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,329.71% | 177.04% | 22.22% | -493.37% | -524.62% |